Investment report on Arena Pharmaceuticals

MicroStockProfit.com announces an investment report featuring Arena Pharmaceuticals Inc. (Nasdaq:ARNA). The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.

ARNA is trading above its 13-day moving average. This is considered to be the sign of a bullish trend. There is added weight to this indication because the moving average is rising and suggests that there has been buying interest in this stock.

Arena Pharmaceuticals Inc. (ARNA) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. The Company's drug candidate, lorcaserin hydrochloride (lorcaserin), is being investigated in a phase 3 clinical trial program for the treatment of obesity. It has a pipeline of compounds that target G protein-coupled receptors (GPCRs), and includes compounds being evaluated independently and with its partners, including Merck & Co. Inc. and Ortho-McNeil-Janssen Pharmaceuticals Inc. On January 9, 2008, the Company acquired from Siegfried Ltd. certain drug product facility assets, including a licensed production facility, fixtures, equipment, other personal property and real estate assets in Zofingen, Switzerland.

Message Board Search for ARNA: http://www.boardcentral.com/boards/ARNA

In the report, the analyst notes:

"ARNA reported a lower net loss in the first quarter of 2010 of $31.3 million, or $0.33 per share, compared to a net loss in the first quarter of 2009 of $50.6 million, or $0.68 per share.

"ARNA recently announced that Eisai Inc. will market lorcaserin for obesity and weight management in the United States following U.S. Food and Drug Administration (FDA) approval under the terms of a marketing and supply agreement between Arena Pharmaceuticals GmbH, a wholly owned subsidiary of ARNA and Eisai. Lorcaserin, which ARNA discovered and has developed for weight management, is intended for obese patients as well as overweight patients who have at least one weight-related co-morbid condition."

To read the entire report visit: http://www.microstockprofit.com/lp/ARNA

SOURCE MicroStockProfit.com